Crescendo Bioscience Vectra crop640

The Vectra DA test from Crescendo Bioscience.

The US Patent and Trademark Office (PTO) has issued a patent for the Vectra DA test by Crescendo Bioscience, San Francisco, a wholly owned subsidiary of Myriad Genetics, Salt Lake City. The patent, which is expected to expire in 2031, provides intellectual property protection for the advanced blood test for adults with rheumatoid arthritis (RA).

Helping patients objectively track their disease activity over time, Vectra DA measures expression levels of 12 biomarkers that are combined into a single score. The biomarkers include CRP, EGF, IL-6, leptin, MMP-1, MMP-3, resistin, SAA, TNF-RI, VCAM-1, VEGF-A, and YKL-40.

The recently issued patent is coassigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA. Crescendo will continue to pursue additional patent applications which, if issued, should expand the scope of intellectual property protection for Vectra DA.

“Crescendo’s first patent for Vectra DA is significant because it validates the innovation required to bring to market the only objective multibiomarker test for assessing RA disease activity,” says Bernie Tobin, president of Crescendo Bioscience. “The PTO’s decision comes at a critical time as we enter the golden era of personalized medicine. In order for personalized medicine to become a reality, strong intellectual property protection is essential because it provides research-based companies like Crescendo with incentives to continue to invest in research and development.”

For more information, visit Crescendo Bioscience.